Sequoia Financial Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 16.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 91,533 shares of the biopharmaceutical company’s stock after buying an additional 13,140 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $2,993,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Pfizer by 0.8% during the second quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after purchasing an additional 3,464,207 shares during the period. State Street Corp increased its holdings in shares of Pfizer by 0.3% during the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after buying an additional 830,299 shares in the last quarter. Capital World Investors increased its holdings in shares of Pfizer by 19.1% during the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after buying an additional 36,092,723 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Pfizer by 12.9% during the first quarter. Wellington Management Group LLP now owns 218,676,145 shares of the biopharmaceutical company’s stock worth $7,137,589,000 after buying an additional 24,950,461 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Pfizer by 1.0% during the first quarter. Geode Capital Management LLC now owns 89,953,885 shares of the biopharmaceutical company’s stock worth $2,931,423,000 after buying an additional 910,123 shares in the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.
PFE has been the subject of several recent analyst reports. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. TheStreet raised shares of Pfizer from a “c+” rating to a “b” rating in a report on Monday, June 1st. Barclays dropped their price objective on shares of Pfizer from $37.00 to $35.00 in a report on Monday, June 1st. SVB Leerink raised their price target on shares of Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, June 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus target price of $39.61.
PFE stock traded down $0.07 during midday trading on Tuesday, reaching $36.94. The company’s stock had a trading volume of 754,446 shares, compared to its average volume of 29,535,438. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97. The stock has a market cap of $205.66 billion, a PE ratio of 14.65, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The business’s 50-day simple moving average is $37.80 and its 200-day simple moving average is $35.68.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. During the same period last year, the firm earned $0.80 earnings per share. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st were paid a $0.38 dividend. The ex-dividend date was Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a yield of 4.11%. Pfizer’s payout ratio is presently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: S&P/TSX Index
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.